Lack of Association of Clinical Factors (SAMe- TT2R2) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background and Purpose Advantages of new oral anticoagulations may be greater in atrial fibrillation (AF) patients of poor anticoagulation control with warfarin. The SAMe-TT2R2 scoring system, based on clinical variables, was recently developed to aid in identifying these patients. In this study, we investigated the association of this clinical composite score with genetic factors related warfarin dosing and the quality of anticoagulation control. Methods Clinical and genetic data were collected from 380 consecutive Korean patients with AF (CHA2DS2-VASc score, 3.5±1.8) who were followed for an average of 4 years. We evaluated factors associated with time in therapeutic range (TTR, INR 2-3), including the CYP2C9 and VKORC1 genotypes and the SAMe-TT2R2 score (Sex female, Age <60 years, Medical history [>two co-morbidities], Treatment [interacting drugs, e.g., amiodarone], Tobacco use within 2 years [doubled], and Race non-white [doubled]). Results The average SAMe-TT2R2 score was 3.4±0.9, range 2-7; and 153 patients (40.2%) had SAMe-TT2R2 scores ≥4. Time in specific INR ranges varied depending on the VKORC1 genotype but not with the CYP2C9 genotype or the SAMe-TT2R2 score. TTR was higher in patients with the VKORC1 1173C>T than in VKORC1 TT (61.7±16% vs. 56.7±17.4%, P=0.031). Multivariate testing showed that VKORC1 genotype but not the SAMe-TT2R2 score was significantly associated with labile INRs. There was no correlation between the SAMe-TT2R2 scores and pharmacogenetic data. Conclusions A genetic factor, but none of the common clinical and demographic factors, as combined in the SAMe-TT2R2 score, was associated with the quality of anticoagulation control in Korean patients with AF.
Abstract
Background and Purpose Advantages of new oral anticoagulations may be greater in atrial fibrillation (AF) patients of poor anticoagulation control with warfarin. The SAMe-TT2R2 scoring system, based on clinical variables, was recently developed to aid in identifying these patients. In this study, we investigated the association of this clinical composite score with genetic factors related warfarin dosing and the quality of anticoagulation control. Methods Clinical and genetic data were collected from 380 consecutive Korean patients with AF (CHA2DS2-VASc score, 3.5±1.8) who were followed for an average of 4 years. We evaluated factors associated with time in therapeutic range (TTR, INR 2-3), including the CYP2C9 and VKORC1 genotypes and the SAMe-TT2R2 score (Sex female, Age <60 years, Medical history [>two co-morbidities], Treatment [interacting drugs, e.g., amiodarone], Tobacco use within 2 years [doubled], and Race non-white [doubled]). Results The average SAMe-TT2R2 score was 3.4±0.9, range 2-7; and 153 patients (40.2%) had SAMe-TT2R2 scores ≥4. Time in specific INR ranges varied depending on the VKORC1 genotype but not with the CYP2C9 genotype or the SAMe-TT2R2 score. TTR was higher in patients with the VKORC1 1173C>T than in VKORC1 TT (61.7±16% vs. 56.7±17.4%, P=0.031). Multivariate testing showed that VKORC1 genotype but not the SAMe-TT2R2 score was significantly associated with labile INRs. There was no correlation between the SAMe-TT2R2 scores and pharmacogenetic data. Conclusions A genetic factor, but none of the common clinical and demographic factors, as combined in the SAMe-TT2R2 score, was associated with the quality of anticoagulation control in Korean patients with AF.
참고문헌 (29)
- Wallentin L, "Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial", Lancet, 376, pp.975~983 (2010)
- Rietbrock S, "How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK general practice research database", Thromb Haemost, 101, pp.527~534 (2009)
- Pisters R, "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)
- Ay H, "Admission international normalized ratio and acute infarct volume in ischemic stroke", Ann Neurol, 64, pp.499~506 (2008)
- Lip GY, "Using the CHADS2 and CHA2DS2-VASc scores for stroke risk prediction as well as the identification of stroke outcomes and cardiac complications in patients with and without atrial fibrillation", Cerebrovasc Dis, 36, pp.281~282 (2013)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Apostolakis S, "Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score", Chest, 144, pp.1555~1563 (2013)
- Boriani G, "Predicting the quality of anticoagulation during warfarin therapy: the basis for an individualized approach", Chest, 144, pp.1437~1438 (2013)
- Kimmel SE, "The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study", Arch Intern Med, 167, pp.229~235 (2007)
- Holbrook AM, "Systematic overview of warfarin and its drug and food interactions", Arch Intern Med, 165, pp.1095~1106 (2005)
- Wells PS, "Interactions of warfarin with drugs and food", Ann Intern Med, 121, pp.676~683 (1994)
- Heck AM, "Potential interactions between alternative therapies and warfarin", Am J Health Syst Pharm, 57, pp.1221~1227 (2000)
- Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the Euro heart survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
- Fang MC, "A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study", J Am Coll Cardiol, 58, pp.395~401 (2011)
- Cho HJ, "Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients", Pharmacogenomics, 8, pp.329~337 (2007)
- Cho HJ, "Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation", Clin Ther, 33, pp.1371~1380 (2011)
- Rosendaal FR, "A method to determine the optimal intensity of oral anticoagulant therapy", Thromb Haemost, 69, pp.236~239 (1993)
- "National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation (clinical guideline 180)"[URL]
- Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
- Furie KL, "Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association", American Stroke Association, 2012, pp.43, 34442~33453
- Larsen TB, "Warfarin or novel oral anticoagulants for atrial fibrillation?", Lancet, 383, pp.931~933 (2014)
- Gallagher AM, "Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients", Thromb Haemost, 106, pp.968~977 (2011)
- Pirmohamed M, "A randomized trial of genotype-guided dosing of warfarin", N Engl J Med, 369, pp.2294~2303 (2013)
- Scott SA, "Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups", Pharmacogenomics, 11, pp.781~791 (2010)
- AFFIRM Investigators, "Atrial Fibrillation Follow-up Investigation of Rhythm Management. Baseline characteristics of patients with atrial fibrillation: the AFFIRM study", Am Heart J, 143, pp.991~1001 (2002)
- Skov J, "SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic", Chest, 145, pp.187~188 (2014)